169 related articles for article (PubMed ID: 31190585)
1. Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center.
Yau P; Jimenez-Zepeda VH; Bailey K; Duggan P; Tay J; Bahlis NJ; Neri P; McCulloch S
Leuk Lymphoma; 2019 Dec; 60(13):3199-3203. PubMed ID: 31190585
[TBL] [Abstract][Full Text] [Related]
2. Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity-induced rash in patients with multiple myeloma.
Shamriz O; Parnasa E; Rubin L; Talmon A; Ribak Y; Lebel E; Vainstein V; Aumann S; Saban R; Gatt ME; Tal Y
Eur J Haematol; 2023 Apr; 110(4):407-413. PubMed ID: 36565290
[TBL] [Abstract][Full Text] [Related]
3. Simple desensitization protocol for multiple myeloma patients with lenalidomide-induced skin rash: Case series.
Sugi T; Mita M; Yasu T; Ohara S; Uchida T; Inoue M; Hagihara M
J Clin Pharm Ther; 2021 Dec; 46(6):1792-1795. PubMed ID: 33960000
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
Lee MJ; Wickner P; Fanning L; Schlossman R; Richardson P; Laubach J; Castells M
Br J Haematol; 2014 Oct; 167(1):127-31. PubMed ID: 24824093
[No Abstract] [Full Text] [Related]
5. A practical 16-day desensitization protocol in lenalidomide-induced non-immediate hypersensitivity reactions.
Demir S; Gelincik A; Coskun R; Ozkan G; Demir N; Paksoy N; Beyaz S; Colakoglu B; Kalayoglu-Besisik S; Nalcacı M; Buyukozturk S
Ann Allergy Asthma Immunol; 2019 Oct; 123(4):394-397. PubMed ID: 31400463
[TBL] [Abstract][Full Text] [Related]
6. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
Barley K; He W; Agarwal S; Jagannath S; Chari A
Leuk Lymphoma; 2016 Nov; 57(11):2510-5. PubMed ID: 26943456
[TBL] [Abstract][Full Text] [Related]
7. Successful desensitization procedure to lenalidomide in a patient with delayed hypersensitivity confirmed with a positive LTT.
Lazzarato I; Gonzalez-Muñoz M; Heredia R; Castellar PharmG FR; López de la Guía A; Cabañas R; Fiandor A; Dominguez-Ortega J
Eur Ann Allergy Clin Immunol; 2020 Sep; 52(5):235-237. PubMed ID: 32374557
[No Abstract] [Full Text] [Related]
8. Successful Capecitabine Desensitization for a Delayed-Type Hypersensitivity Reaction.
Demir S; Olgac M; Saglam S; Gelincik A; Colakoglu B; Buyukozturk S
J Investig Allergol Clin Immunol; 2016; 26(1):66-7. PubMed ID: 27012024
[No Abstract] [Full Text] [Related]
9. [Lenalidomide desensitization in a patient with 5q- syndrome].
Boudin L; Patient M; Roméo E; Bladé JS; de Jauréguiberry JP
Bull Cancer; 2017 Sep; 104(9):814-816. PubMed ID: 28778340
[No Abstract] [Full Text] [Related]
10. Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide.
Schoenbeck KL; Wildes TM
Clin Interv Aging; 2020; 15():619-633. PubMed ID: 32440105
[TBL] [Abstract][Full Text] [Related]
11. Pyoderma gangrenosum induced by lenalidomide in a case of multiple myeloma.
Meunier M; Larabi A; Schacherer M; Deteix C; Courby S; Cahn JY
Ann Hematol; 2020 Feb; 99(2):379-380. PubMed ID: 31822948
[No Abstract] [Full Text] [Related]
12. [Very low-dose lenalidomide therapy for elderly multiple myeloma patients].
Minagawa K; Kawano H; Suzuki T; Inagaki T; Kishi M; Hirata T; Kimura S; Takechi M; Koide T; Iwai M; Katayama Y; Matsui T
Rinsho Ketsueki; 2013 May; 54(5):457-62. PubMed ID: 23727684
[TBL] [Abstract][Full Text] [Related]
13. Pomalidomide desensitization for hypersensitivity: A case report.
Park JJ; Huang E; Monteleone CA; Kane MP; Cooper DL
J Oncol Pharm Pract; 2020 Jul; 26(5):1244-1247. PubMed ID: 31822201
[TBL] [Abstract][Full Text] [Related]
14. Human leukocyte antigen genotypes and trial of desensitization in patients with oxcarbazepine-induced skin rash: a pilot study.
Lee B; Yu HJ; Kang ES; Lee M; Lee J
Pediatr Neurol; 2014 Aug; 51(2):207-14. PubMed ID: 25079569
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide Desensitization for Delayed Cutaneous Reaction: A Case Series and Review of the Literature.
Ali SB; Lee WI; Horvath N; Le TA; Smith W; Hissaria P
J Allergy Clin Immunol Pract; 2023 May; 11(5):1503-1508. PubMed ID: 36738926
[TBL] [Abstract][Full Text] [Related]
16. [Successful management of drug-induced skin rash in a relapsed multiple myeloma patient with pomalidomide desensitization].
Hagihara M; Ide S; Ohara S; Uchida T; Inoue M; Hua J
Rinsho Ketsueki; 2019; 60(2):137-139. PubMed ID: 30842382
[TBL] [Abstract][Full Text] [Related]
17. [Immunomodulator drugs for the treatment of multiple myeloma].
Fernández-Lázaro D; Fernández-Lázaro CI; Caballero García A; Córdova Martínez A
Rev Med Chil; 2018 Dec; 146(12):1444-1451. PubMed ID: 30848748
[TBL] [Abstract][Full Text] [Related]
18. Phase II Clinical Trial of Lenalidomide and Dexamethasone Therapy in Japanese Elderly Patients With Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide.
Kobayashi T; Miura M; Niioka T; Abumiya M; Ito F; Kobayashi I; Ikeda S; Yoshioka T; Kameoka Y; Takahashi N
Ther Drug Monit; 2018 Jun; 40(3):301-309. PubMed ID: 29494421
[TBL] [Abstract][Full Text] [Related]
19. Desensitization in delayed drug hypersensitivity reactions -- an EAACI position paper of the Drug Allergy Interest Group.
Scherer K; Brockow K; Aberer W; Gooi JH; Demoly P; Romano A; Schnyder B; Whitaker P; Cernadas JS; Bircher AJ;
Allergy; 2013 Jul; 68(7):844-52. PubMed ID: 23745779
[TBL] [Abstract][Full Text] [Related]
20. Successful desensitization protocol for delayed cutaneous eruption to temozolomide.
Clayton E; Madamba J; Kong XT; Braskett M
J Allergy Clin Immunol Pract; 2014; 2(5):626-8. PubMed ID: 25213062
[No Abstract] [Full Text] [Related]
[Next] [New Search]
